Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kaltura Inc (KLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kaltura Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Kaltura Inc trades at $1.25 (market cap $193.23M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 23.2× Kaltura Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | KLTR | |
|---|---|---|
Market Cap | $4.49B | $193.23M |
Sector | Health | Technology |
52-Week High | $28.06 | $2.01 |
52-Week Low | $20.06 | $1.08 |
Enterprise Value | $3.69B | $175.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Kaltura (KLTR) trades at $1.29, up 2.38% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, though it remains unprofitable with negative margins. Recent industry recognition and AI product launches highlight strategic positioning in digital experience platforms.
Investment outlook balances operational improvements against persistent profitability challenges. Positive analyst sentiment (44% buy ratings) and strong institutional coverage suggest potential upside if AI initiatives drive growth, but high P/B ratio and negative cash flow pose risks for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
